22 years of experience working with global therapeutics developers with specific expertise in cell therapy and regenerative medicine.
Founder and President of Galen Therapeutics, a regenerative medicine company focusing on pain prevention in the diseases of the spine.
Ex head of program management and general manager for 3 assets at Mana Therapeutics, a company focusing on allogeneic TCR based cell therapies, responsible for success of the portfolio including corporate manufacturing strategy.
Led R&D, Clinical Transformation Strategy and Translational Research practices at ZS Associates, IQVIA and Deloitte Consulting respectively, working with biotechnology / pharmaceutical sponsors helping improve R&D and manufacturing operations.
Tunç's academic background includes a MS in Biotechnology with training in advanced Immunology from the Johns Hopkins University, and an MBA and BS in Mechanical Engineering both from Duke University.